Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 1 July 1977:
Vol. 197. no. 4298, pp. 74 - 77
DOI: 10.1126/science.325650
Prev | Table of Contents | Next

Articles

Science, Vol 197, Issue 4298, 74-77
Copyright © 1977 by American Association for the Advancement of Science

articles

Intravenous naloxone administration in schizophrenia and affective illness

GC Davis, WE Bunney Jr, EG DeFraites, JE Kleinman, DP van Kammen, RM Post, and RJ Wyatt

Fourteen schizophrenic patients and five patients with affective disorders were given naloxone (0.4 to 10 milligrams) or placebo intravenously in a double-blind fashion. Physicians' ratings of hallucinations, mannerisms and posturing, conceptual disorganization, psychosis, and mood did not change significantly. A single item, unusual thought content, improved significantly on the naloxone day compared to the placebo day. There was no improvement in mood in affectively ill patients rated either by themselves or by physicians. Naloxone did not markedly improve any patient studied, which suggests that the acute blockade of opiate receptors is not associated with global improvement in psychotic symptomatology.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders.
A.J. Stoessl (1989)
J Psychopharmacol 3, 99-120
   PDF »
Long-term Pimozide Pretreatment Differentially Affects Behavioral Responses to Dextroamphetamine in Schizophrenia: Further Exploration of the Dopamine Hypothesis of Schizophrenia.
D. P. van Kammen, J. P. Docherty, S. R. Marder, J. N. Rayner, and W. E. Bunney Jr (1982)
Arch Gen Psychiatry 39, 275-281
   Abstract »    PDF »
Short-term Naloxone Administration in Schizophrenic and Manic Patients: A World Health Organization Collaborative Study.
D. Pickar, F. Vartanian, W. E. Bunney Jr, H. P. Maier, M. T. Gastpar, R. Prakash, B. B. Sethi, R. Lideman, B. S. Belyaev, M. V. A. Tsutsulkovskaja, et al. (1982)
Arch Gen Psychiatry 39, 313-319
   Abstract »    PDF »
{beta}-Endorphin: Intravenous Infusion Causes Behavioral Change in Psychiatric Inpatients.
R. H. Gerner, D. H. Catlin, D. A. Gorelick, K. K. Hui, and C. H. Li (1980)
Arch Gen Psychiatry 37, 642-647
   Abstract »    PDF »
Naloxone-Induced Behavioral and Physiological Effects in Normal and Manic Subjects.
L. L. Judd, D. S. Janowsky, D. S. Segal, and L. Y. Huey (1980)
Arch Gen Psychiatry 37, 583-586
   Abstract »    PDF »
Plasma beta-endorphin immunoreactivity in schizophrenia.
M Ross, P. Berger, and A Goldstein (1979)
Science 205, 1163-1164
   Abstract »    PDF »
Basic and Clinical Studies of Endorphins.
W. E. BUNNEY Jr., C. B. PERT, W. KLEE, E. COSTA, A. PERT, and G. C. DAVIS (1979)
Ann Intern Med 91, 239-250
   Abstract »    PDF »
Pituitary hormones in brain: where, how, and why?.
D. Krieger and A. Liotta (1979)
Science 205, 366-372
   Abstract »    PDF »
Improvement of Schizophrenic Patients Treated With Des-Tyr1]-{gamma}-endorphin (DT{gamma}E).
W. M. A. Verhoeven, H. M. van Praag, J. M. van Ree, and D. de Wied (1979)
Arch Gen Psychiatry 36, 294-298
   Abstract »    PDF »
Some Observations on the Opiate Peptides and Schizophrenia.
S. J. Watson, H. Akil, P. A. Berger, and J. D. Barchas (1979)
Arch Gen Psychiatry 36, 35-41
   Abstract »    PDF »
beta-Endorphin is not detectable in plasma from normal human subjects.
T Suda, A. Liotta, and D. Krieger (1978)
Science 202, 221-223
   Abstract »    PDF »
Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.
S. Watson, P. Berger, H Akil, M. Mills, and J. Barchas (1978)
Science 201, 73-76
   Abstract »    PDF »
Endorphins in Psychiatry: An Overview and a Hypothesis.
K. Verebey, J. Volavka, and D. Clouet (1978)
Arch Gen Psychiatry 35, 877-888
   Abstract »    PDF »
Behavioral neurochemistry: neuroregulators and behavioral states.
J. Barchas, H Akil, G. Elliott, R. Holman, and S. Watson (1978)
Science 200, 964-973
   Abstract »    PDF »
{beta}-Endorphin-Induced Changes in Schizophrenic and Depressed Patients.
N. S. Kline, C. H. Li, H. E. Lehmann, A. Lajtha, E. Laski, and T. Cooper (1977)
Arch Gen Psychiatry 34, 1111-1113
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)